HF 0420

Drug Profile

HF 0420

Alternative Names: HF0420; Oligotropin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Loyola University Chicago
  • Developer Hunter-Fleming; Loyola University Chicago
  • Class Glycosaminoglycans; Heparins; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Peripheral nervous system diseases
  • Discontinued Alzheimer's disease; CNS trauma; Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Peripheral-nervous-system-diseases(Prevention) in Italy (PO)
  • 14 Oct 2009 Newron returns HF 0420 rights to inventor, Umberto Cornelli of Loyola University
  • 05 Apr 2006 This compound is still in active development for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top